Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 8;12:960808. doi: 10.3389/fonc.2022.960808

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Lasagni, Leonardi, Pivetti, Di Marco, Ravaioli, Serenari, Gitto, Critelli, Milosa, Romanzi, Mancarella, Dituri, Riefolo, Catellani, Magistri, Romagnoli, Celsa, Enea, de Maria, Schepis, Colecchia, Cammà, Cescon, d’Errico, di Benedetto, Giannelli, Martinez-Chantar and Villa

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Immunohistochemical analysis of angiopoietin-2 in endothelia of primary and recurrent HCCs after LT. Immunostaining for angiopoietin-2 (20×) shows marked cytoplasmic and vascular endothelial positivity both in primary HCCs at explant (A, C, E, G) and in the respective recurrent tumors (B: liver; D: peritoneum; F: lung; H: kidney). Endothelial and parenchymal angiopoietin-2 expression in hepatic and extra-hepatic recurrent HCCs is more marked than in the corresponding primary tumor. Arrows indicate representative endothelial localization (scale bar: 6.7 μm).